Botulinum toxin injection for vocal cord dysfunction in asthma

Botulinum toxin injection for vocal cord dysfunction in asthma - benefits on symptoms and laryngeal imaging

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12613000455763

Enrollment

Registered

2013-04-19

Start date

2012-08-28

Completion date

2013-03-05

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The study aims to provide proof-of-concept support for the use of botulinum toxin in difficult-to-treat asthma with vocal cord dysfunction.

Interventions

Botulinum toxin injection of unilateral vocal cord. Injection done in 3 ways: through skin under electromyography, through the skin under endoscopic guidance and direct injection under general anesthetic. Dose 2.5-5U per injection. Observation for 3 months. Repeat injection after 1-3 months if symptoms recurrent (ACT score same or lower than baseline). Injection technique was at the discretion of the ENT surgeon and doses were based on his experience injecting vocal cord dystonias (>300 cases).

Study design

Allocation

Non-randomised trial

Intervention model

Single group

Primary purpose

Treatment

Masking

Open (masking not used)

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

Difficult-to-treat asthma unresponsive to optimised treatments, Vocal cord dysfunction on imaging, ACT score <15

Exclusion criteria

Allergy to botulinum toxin Other known laryngeal disease

Outcome results